Meeting
2023 ASCO Annual Meeting
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
Authors
Cyrille Touzeau
University Hospital of Nantes, France, Nantes, France
Cyrille Touzeau , Xavier P Leleu , Clara Mariette , Salomon Manier , Sabine Brechignac , Laure Vincent , Benjamin Hebraud , Olivier Decaux , Samantha Schulmann , Caroline Lenoir , Pascal Godmer , Agathe Farge , Laure Peyro Saint Paul , Jean-Jacques Parienti , Margaret Macro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03757221
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8054)
DOI
10.1200/JCO.2023.41.16_suppl.8054
Abstract #
8054
Poster Bd #
46
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew J Yee
Poster
2017 ASCO Annual Meeting
Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.
First Author: Maria-Victoria Mateos
Poster
2013 ASCO Annual Meeting
Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.
First Author: David Samuel DiCapua Siegel
Poster
2013 ASCO Annual Meeting
Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.
First Author: Sundar Jagannath